Drug Projected at $1 Million Has Spark Mulling Installment Plan

Drugmaker Spark Therapeutics Inc. is considering installment payments for a promising gene therapy for blindness that analysts are projecting will come with a hefty price tag.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.